Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of acromegaly
Received previous radiation and/or surgical treatment for their GH (Growth Hormone) producing pituitary adenoma and have required medical therapy due to failure to normalize GH (Growth Hormone) and/or IGF-I as a result of their primary treatment
Patients that been receiving Sandostatin LAR for a minimum of 6 months prior to enrollment
You may not be if
Presence of other conditions that may result in abnormal GH (Growth Hormone) and/or IGF-I concentrations
Patients on current medical therapy other than Sandostatin LAR
AST/ALT \>= 3xULN (upper limits of normal)
Pituitary adenoma within 3mm of optic chiasm confirmed by recent MRI
Visual field defects (except post-surgical stable residual defects)
Unable to self administer drug
Radiotherapy within 12 months of entering the study
